

GLAXOSMITHKLINE PLC  
Form 6-K  
October 10, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1566.36 pence per Share on 7 October 2013, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 3 October 2013.

	Ordinary Shares
Sir Andrew Witty	878.465
Dr M M Slaoui	239.911
Mr S M Bicknell	145.117
Mr R G Connor	39.290
Mr S A Hussain	1,144.938
Mr D S Redfern	347.249
Ms C Thomas	386.704
Mr P C Thomson	114.758
Dr P J T Vallance	351.001
Ms E Walmsley	153.396
Mr C Weber	352.131

The Company was advised of this information on 9 October 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

10 October 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 10, 2013

By: SIMON BICKNELL

-----

Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc